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Abstract
Background: Glucocorticoids are commonly used in the clinical setting for their potent anti-inflammatory effects;
however, significant variations in response to treatment have been demonstrated. Although the underlying mechanisms
have yet to be fully understood, this variable response may be a result of alterations in human glucocorticoid receptor
(hGR) expression and function. In addition to hGRα, the biologically active isoform, a screening of current databases and
publications revealed five alternative splice isoforms and hundreds of variants that have been reported to date. Many of
these changes in the hGR-coding gene, NR3C1, have been linked to pathophysiology. However, many studies focus on
evaluating hGR expression in vitro or detecting previously reported variants.
Results: In this study, blood from healthy volunteers, burn and asthma patients, as well as from peripheral blood
mononuclear cells isolated from leukoreduced donor whole blood, were screened for NR3C1 isoforms. We identified
more than 1500 variants, including an additional 21 unique splice isoforms which contain 15 new cryptic exons. A
dynamic database, named the Universal hGR (UhGR), was created to annotate and visualize the variants.
Conclusion: This identification of naturally occurring and stress-induced hGR isoforms, as well as the establishment of an
hGR-specific database, may reveal new patterns or suggest areas of interest that will lead to the improved understanding
of the human stress response system.
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Background
Glucocorticoids are a class of steroid hormones associated
with many biological processes including inflammation
and immune response. Synthetic glucocorticoids have be-
come one of the most common pharmacologic therapies
for conditions such as asthma, autoimmune disorders,
and sepsis. However, the clinical use of glucocorticoids
has been complicated by hypersensitivity, drug resistance,
and pervasive side effects [1–4]. During a post-injury sys-
temic inflammatory response, the glucocorticoid pathway
is essential to mounting the anti-inflammatory response
needed to return the body to homeostasis [5]; however,
there can be wide variations in individual responses to
seemingly identical physiologic stressors. These variations
may be influenced, in part, by an individual’s regulation
and expression of human glucocorticoid receptor (hGR)
isoforms. Improved understanding of hGR expression and
function may offer solutions to the limitations of
therapeutic glucocorticoids and aid in understanding the
pathophysiology of disease [6].
hGR is a ligand-inducible and ubiquitously expressed
nuclear hormone receptor that is part of the
hypothalamic-pituitary-adrenal (HPA) axis, where it is in-
volved in attenuating the stress response. Being lipophilic,
glucocorticoids diffuse across the cellular membrane
where they bind to hGR, their intracellular receptor that
resides primarily unbound in the cytoplasm [7]. The
glucocorticoid/hGR complex undergoes conformational
changes and translocates to the nucleus where it binds to
glucocorticoid response elements (GREs) and then inter-
acts with co-regulators that assist with hGR’s transcrip-
tional activities [7].
The hGR is encoded by the NR3C1 gene, located on
Chromosome 5 (5q31–32) [8], and consists of nine
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exons [9], of which most of exons two through nine are
translated (Fig. 1a). Due to alternative splicing, there are
multiple variants of the non-coding exon one [10], as
well as two variants of exon nine. The biologically active
isoform is hGRα, which codes for a 777 amino acid pro-
tein that is composed of four domains: a transactivation
domain, a DNA-binding domain, a hinge region, and a
ligand-binding domain (Fig. 1b) [11]. Since 1985, when
hGRα and its dominant negative inhibitor (hGRβ) were
first identified [9, 12], additional alternative splice iso-
forms (hGRγ, hGR-A, hGR-P) and hundreds of novel
single nucleotide polymorphisms (SNPs) have also been
recognized [13–15].
Several alternative splice variants of hGR have been
found to have pathologic implications. hGRβ, which differs
from hGRα due to the alternative splicing of exon 9, has
been linked a multitude of diseases such as glucocorticoid-
insensitive asthma [16], pediatric acute lymphoblastic
leukemia [17], glucocorticoid-resistant ulcerative colitis
[18], and cancer [19–21]. High expression levels of hGRγ, a
variant that contains an additional alanine, has been associ-
ated with exogenous glucocorticoid resistance in children
with acute lymphoblastic leukemia [22]. Another splice
variant, hGR-P, terminates in the retained intron G and has
been found to be expressed in both normal cells and those
derived from subjects with Cushing’s syndrome and several
cancer types, including multiple myeloma, acute lympho-
blastic leukemia, and non-Hodgkin’s lymphoma [23, 24].
Additionally, late-stage glucocorticoid-resistance cells, de-
rived from an immortalized multiple myeloma line, had
greater expression of hGR-P than in cells representing
early-stage resistance, indicating the isoform potentially
could contribute to resistance development [25]. However,
despite numerous studies that have linked alternative splice
variants to a variety of diseases, their specific roles have yet
to be fully understood.
In addition to splice variants, single nucleotide
changes can also have a profound physiological impact.
Two of the most commonly studied SNP sites (N363S
and ER22/23EK) cause altered, but opposing, responsive-
ness to glucocorticoids in vivo [26]. The A1088G SNP
(rs56149945, NM_000176.2:c.1088A > G), which results
in the amino acid change N363S, has been found to
increase sensitivity to glucocorticoids [27] which can
increase an individual’s risk for medical conditions such
as coronary artery disease [28], obesity [29], and other
illnesses. Contrastingly, a combination of two SNPs
(GAG|AGG→GAA|AAG) produces the E22E and
Fig. 1 Diagram of NR3C1: the human glucocorticoid receptor (hGR) gene. a The hGR gene, NR3C1, is located on Chromosome 5q31–32 and is
composed of one untranslated exon (exon 1) and eight coding exons (2–9). Alternative splicing of exon 9 results in two isoforms, hGRα and
hGRβ, and the splice junction is indicated with a vertical dashed line. Relative intron (A→ H) locations are shown above the gene. b hGRα, the
biologically active isoform, codes for a 777 amino acid protein that is made up of four domains: transactivation domain, DNA-binding domain
(DBD), hinge region (H), and ligand-binding domain (LBD). hGRβ arises from alternative splicing of exon 9 to produce a 742 amino acid protein
where the last fifteen amino acids differ from hGRα. Shaded areas in the exons match the different domains. Start and stop codons are indicated
on the coding sequence with vertical lines
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R23K isoform, denoted as ER22/23EK (rs6189/rs6190,
NM_000176.2:c.[66G > A;68G > A]), which has been
linked to glucocorticoid insensitivity and reportedly con-
fers such health benefits as a decreased risk of dementia
[30] and lower insulin and LDL cholesterol levels [31].
Many papers have reported numerous hGR variants
but because of the scale and complexity of the gene, it is
difficult to track the rapidly expanding list of the identi-
fied sequence changes. Although several databases exist
to catalog genome-wide variants, studies have shown
that curated databases which focus on specific genes (or
‘locus-specific databases’ [LSDBs]) have twice as many
unpublished variants as published ones, indicating the
need for LSDBs in genetic research [32]. Unfortunately,
hGR lacks a comprehensive and up-to-date LSDB. We
believe that the extreme diversity already discovered in
the NR3C1 gene warrants the need for a modified LSDB
system that would allow for both dynamic annotation
and analysis of variations. This database would be a
valuable tool for identifying correlations between hGR
variants and an individual patient’s response to both
injury and glucocorticoid treatment.
To better understand the impact of hGR variations, we
have explored the NR3C1 gene in two populations:
volunteers (i.e., healthy adults) and people suffering from
burns or asthma (i.e., medical conditions that have vari-
able responsiveness to glucocorticoid treatment). Several
isoforms have already been described but our laboratory
has identified many more. These variants, in addition to
those already published in journal articles and public da-
tabases, serve as the foundation for a new LSDB-style
system created for the curation and analysis of data,
named the Universal hGR.
Results
Alternative splice isoforms
To survey for published splice variants, PubMed and se-
veral NR3C1 LSDBs were searched, and five alternative
splice variants identified (Fig. 2a). hGRβ arises from alterna-
tively spliced exon 9, resulting in a 742 amino acid protein,
of which the first 727 match the 777 amino acids in hGRα
[12]. First identified in 1999, hGRγ reportedly comprises
3.8–8.7% of normal GR expression and has three base pairs
(+GTA) retained between exons 3 and 4, introducing an
extra arginine in the DNA-binding domain (DBD) that re-
duces the transcriptional activation of hGRα by half [14].
hGR-P and hGR-A were both discovered in 1993 in a
glucocorticoid-resistant human multiple myeloma cell line
[15]. hGR-P retains a portion of intron G, which contains
an early stop codon that results in a 676 amino acid
protein, of which amino acids 1–674 match hGRα, and is
missing a portion of the ligand-binding domain (LBD).
hGR-A lacks exons 5 through 7, generating a 592 amino
acid protein that has a truncated hinge region and LBD.
First reported in 2007, hGR Δ313–338 has a 78 nucleotide
deletion in exon 2 that results in a protein that lacks amino
acids 313–338 in the transactivation domain [33].
In our laboratory, we screened two populations (healthy
and stressed) for their hGR variant profiles and a total of 21
novel splice isoform variations have been identified so far
(Fig. 2b). Although the isoforms were illustrated based on
the hGRα structure, it should be noted that additional
variants may occur due to alternate start sites or exon 9
splicing to produce the hGRβ terminus. The isoforms were
given a name with a “hGR” prefix followed by a systematic-
ally determined suffix representing the change in the cod-
ing DNA sequence. Deletions were indicated by a delta (Δ)
followed by the affected exon and, if only a segment of the
exon is deleted, the exact number of base pairs missing is
indicated. When multiple exons are altered, the numbers
are listed in order of 5′ to 3′ and separated with commas.
Similarly, insertions were identified using the same naming
conventions but with the delta replaced with a hyphen and
retained portions of intron were designated using the same
format as exonic insertions. The sole departure from this
system occurs when the alteration includes an established
alternative splice variant (e.g., hGRγ); that segment of the
name matched the established variant rather than repre-
senting the precise sequence change. Nucleotide changes
were also used to describe the variants with the nomencla-
ture proposed by the Human Genome Variation Society
(HGVS) (Table 1) [34].
Of our newly reported 21 splice isoforms, several
affect large portions, or the entirety, of exons or introns.
Our findings include a previously published isoform,
hGR-H (previously published as hGR-S1), that retains all
526 bp of intron H, which contains an early stop codon
and results in a truncated protein of 745 amino acids
[35]. hGRΔ7(52) lacks the 52 nucleotides at the 5′ end
of exon 7 and hGRΔ3,4 lacks exons 3 and 4; these code
for putative proteins that are 662 and 417 amino acids,
respectively. hGR-γ/H has a 3 base pair insertion be-
tween exons 3 and 4, matching hGRγ, but also retains
intron H, similar to hGR-H.
The remaining 17 novel splice variants are the result of 15
different retained intron sections. For all of them, we verified
the presence of splice donor and acceptor sites which con-
firms their characterization as new cryptic exons. Intron B is
the largest intron and predictably yielded the greatest num-
ber of variants. This includes hGR-B(59) (59 nucleotides
retained), hGR-B(122) (122 nucleotides), hGR-B(1015) (1015
nucleotides), hGR-B(93) (93 nucleotides), hGR-B(77) (77 nu-
cleotides), and hGR-B(54) (54 nucleotides); each new exon
contains an early stop codon, resulting in putative proteins
of 395, 403, 402, 416, 395, and 402 amino acids, respectively.
Combinations of these new exons from intron B were also
seen in hGR-B(93,54), which has both the 93 and 54 nucleo-
tide exons, and hGR-B(93,77), which contains both the 93
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Fig. 2 (See legend on next page.)
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and 77 nucleotide exons. hGR-B(93,46,77) has the 93 and
77 nucleotide exons flanking a 46 nucleotide exon, and
hGR-B(93,796) has the 93 nucleotide exon followed by a
796 nucleotide exon. Additionally, we also found an isoform,
hGR-B(77)/H, which has the 77 nucleotide exon and
retained intron H. All the splice variants were found in hu-
man subjects, except for hGR-B(122) which was found only
in tsA201 cells so far.
The other splice variants retain sections from introns
D and G. Three new exons were discovered in intron D:
one that is 176 nucleotides in length, hGR-D(176); an-
other that is 177 nucleotides, hGR-D(177); and lastly,
one that is 87 nucleotides, hGR-D(87). These splice vari-
ants code for putative proteins that are 506, 493, and
504 amino acids, respectively, and all are missing por-
tions of the hinge region and the entirety of the LBD.
Interestingly, the retained introns from hGR-D(176) and
hGR-D(177) have 145 overlapping nucleotides. Lastly, in
intron G, hGR-G(44) retains 44 nucleotides,
hGR-G(117) retains 117 nucleotides, and hGR-G(93) re-
tains 93 nucleotides, resulting in proteins that are miss-
ing a portion of the LBD and are 677, 690, and 704
amino acids, respectively.
Single nucleotide polymorphisms (SNPs)
From a survey of public databases and publications to
look for reported nucleotide substitutions, 758 SNPs
have been cataloged (Fig. 3a). The majority of these were
(See figure on previous page.)
Fig. 2 Coding sequences and protein structures of splice variants. a The coding sequences and putative protein structures for hGRα and the five
published splice variants of hGR are shown. Vertical lines indicate the location of the start codon (ATG) and stop codon (S), along with the four
domains: transactivation, DNA-binding domain (DBD), hinge region (H) and ligand-binding domain (LBD). Protein structures have amino acid
lengths noted and sequence variations relative to hGRα are indicated with hatched lines. b Diagram of the coding sequences and putative
protein structures for the 21 splice variants identified by our laboratory. *Previously published as hGR-S1 [35]
Table 1 HGVS nomenclature for novel hGR splice variants
Isoform RNA
[NG_009062.1(NM_000176.2):]
Protein
[NG_009062.1(NM_000176.2):]
hGR-H r.2181_2182ins2181+1_2182-1 p.(Val729Serfs*18)
hGRΔ7(52) r.1973_2023del p.(Val658Phefs*6)
hGRΔ3,4 r.1185_1468del p.(Pro396Serfs*23)
hGR-γ/H r.[1351_1352ins1351+1_1351+3;2181_2182ins2181+1_2182-1] p.(Gly451_Gln452insArg;Val729Serfs*18)
hGR-B(59) r.1184_1185ins1184+9720_1184+9778 p.(Ser395Argfs*2)
hGR-B(122) r.1184_1185ins1184+15187_1184+15308 p.(Pro396Leufs*9)
hGR-B(1015) r.1184_1185ins1185-39571_1185-38557 p.(Ser395Argfs*9)
hGR-B(93) r.1184_1185ins1185-24908_1185-24816 p.(Pro396Thrfs*22)
hGR-B(77) r.1184_1185ins1185-13046_1185-12970 p.(Pro396Thrfs*22)
hGR-B(54) r.1184_1185ins1185-9161_1185-9108 p.(Ser395Argfs*9)
hGR-B(93,54) r.1184_1185ins[1185-24908_1185-24816;1185-9161_1185-9108] p.(Pro396Thrfs*22)
hGR-B(93,77) r.1184_1185ins[1185-24908_1185-24816;1185-13046_1185-12970] p.(Pro396Thrfs*22)
hGR-B(93,46,77) r.1184_1185ins[1185-24908_1185-24816;1185-20820_1185-20775;1185-13046_1185-12970] p.(Pro396Thrfs*22)
hGR-B(93,796) r.1184_1185ins[1185-24908_1185-24816;1185-20552_1185-19757] p.(Pro396Thrfs*22)
hGR-B(77)/H r.[1184_1185ins1185-13046_1185-12970;2181_2182ins2181+1_2182-1] p.(Arg395Serfs*2)
hGR-D(176) r.1468-1469ins1468+618_1468+793 p.(Ala490Glyfs*18)
hGR-D(177) r.1468-1469ins1468+649_1468+825 p.(Ala490Aspfs*5)
hGR-D(87) r.1468-1469ins1468+4219_1468+4305 p.(Ala490Aspfs*16)
hGR-G(44) r.2023_2024ins2023+5996_2023+6039 p.(Val675Glufs*4)
hGR-G(93) r.2023_2024ins2024-2043_2024-1951 p.(Val675Glyfs*31)
hGR-G(117) r.2023_2024ins2024-1586_2024-1470 p.(Val675Glufs*17)
Leventhal et al. BMC Genetics           (2019) 20:16 Page 5 of 15
cataloged in the National Center for Biotechnology In-
formatics (NCBI) databases, while an additional three
SNPs were reported in other databases and nine SNPs in
publications. Out of the 758 SNPs, 342 SNPs are in the
coding region, with 226 in the transactivation domain,
16 in the DBD, 16 in the hinge region, and 84 in the
LBD. Of those, 226 are non-synonymous, including 5
SNPs which cause premature termination. We also
screened portions of the hGR introns to identify SNPs in
the regions that correspond to our newly found cryptic
exons described above. From this search, 130, 18, and 7
SNPs were found in introns B, D, and G, respectively
(Fig. 4). There were 54 documented SNPs in the entirety
of intron H (Fig. 4). The remaining SNPs were located
in the 5′ and 3′ untranslated regions (UTRs). In the
other databases, an additional 28 SNPs were found that
had not yet been annotated in NCBI’s SNP database;
however, these were located in non-coding areas which
are not our focus at this time.
In comparison, our laboratory has identified 1497
SNPs, of which only 124 have been previously re-
ported (Fig. 3a and b). There are 1465 SNPs in the
coding region: 647 in the transactivation domain, 153
in the DBD, 101 in the hinge region, and 564 in the
LBD. Of those, we found that 478 are synonymous
SNPs and 987 are non-synonymous, including 39 that
cause premature termination. When screening the
hGR intron regions that correspond to our new
cryptic exons to detect SNPs, only 9 SNPs were iden-
tified in intron B and 7 in intron H (Fig. 4), with the
remaining 16 being located in the first 303 base pairs
of the 3’UTR. Of the 1497 total SNPs, 718 were
found in multiple clones. Due to the small population
size, SNP frequency was not evaluated. Additionally,
to pursue atypical isoforms, the number of samples
sequenced varied among subjects and conditions and
thus would not be a fair representation of the fre-
quency of a SNP in a true population.
Insertions/deletions
In addition to SNPs, databases and publications were
also screened for insertions and deletions. A total of 25
insertions and 22 deletions were reported (Fig. 5b). Only 3
variants caused frameshifts: 1 single-base-pair insertion in
the transactivation domain and 2 multiple-base-pair dele-
tions in the LBD. Two more deletions were in frame, and
the remaining insertions and deletions were located in ei-
ther in introns or the 3’UTR. One deletion/insertion
(NM_001018077.1:c.66_68delinsAAA, p.Arg23Lys) was
reported solely in the Leiden Open Variation Database
(LOVD).
Conversely, our laboratory cataloged 15 insertions and
117 deletions, none of which had been previously reported
(Fig. 5a). Of the 15 insertions, 13 were located in exons
and therefore caused frameshifts. All 13 were single nu-
cleotide insertions, and only 4 occurred in multiple clones.
The additional two single nucleotide inserts were located
in non-coding regions, with one insertion in the 3’UTR
and the other, which was found in multiple clones, in in-
tron H. Of the 117 deletions, 81 were single nucleotides.
Fig. 3 Summary of single nucleotide polymorphisms (SNPs). b The table shows the number of SNPs in each exon that were found in our hGR
screenings compared to the survey of the dbSNP and publications. Our screenings identified 1481 SNPs in exons 2 through 9: 1465 in the coding
regions and an additional 16 in the 3’UTR. The corresponding domains are shown on the top: Transactivation (Tran.), DNA-binding domain (DBD),
hinge region (H), and ligand-binding domain (LBD), as well as the 5′ and 3′ untranslated regions (UTR). Intronic SNPs are not shown. b A
representation of SNPs (found in six or more clones) from our screening is displayed with the nucleotide change indicated above the isoform.
Domains are indicated with shading. Green, italic = synonymous substitution; Red = premature termination
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The transactivation domain had 27 deletions, the DBD
had 9, the hinge region had 47, the LBD had 25, the first
303 base pairs of the 3’UTR had 7, and the remaining 2
deletions occurred in introns. For 38 of the deletions, the
variant was found in multiple clones.
The universal hGR database (UhGR)
To collect and collate the hGR variations identified from
the different studies conducted in our laboratory, the
Universal hGR (UhGR) database was created. Named
the Universal hGR due to the inclusive nature of the
Fig. 4 Polymorphisms in new exon sequences. Diagram shows relative positions of retained intron sequences that were found during the hGR
screening which includes 14 new exons and intron H. Variations from the reference hGR intron sequence, indicated by a vertical line and
substituted nucleotide, are shown above the retained sequence structure if detected in our laboratory’s hGR screening, or below if found in the
survey of databases and publications. The two nucleotides immediately before and after the exons are indicated to show the splice acceptor sites
(AG; solid blue line) and splice donor sites (GT; solid red line)
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database, the UhGR is currently built on a series of Excel
worksheets (Microsoft) until a formal software suite can
be constructed. The source data consisted of our labora-
tory hGR clone collection generated from volunteers,
burn patients, asthma patients, human Leukopaks, and
tsA201 cells. Each clone was assigned a unique identifier
(CloneID). Each CloneID was then annotated with infor-
mation regarding the source (subject demographics, pa-
tient disease conditions, PCR amplification conditions,
etc.) The clone sequence was then analyzed to identify
variants, each of which was assigned a unique identifier
(Variant ID). The variant IDs were not unique to each
CloneID, so the prevalence of each variant could be de-
termined across the dataset or analyzed for possible
clustering within subject groups. Any coding changes
(altered amino acid, early termination) were also noted.
This information was used to construct the UhGR
(Fig. 6).
To visualize the changes in sequence due to the
variations, the NCBI reference sequence for hGR
(NM_000176.2) was displayed on a spreadsheet within the
UhGR. Each variant ID was added to the reference se-
quence with the nucleotide changes noted; SNPs and dele-
tions were identified in neighboring columns while
insertions were directly added to the reference sequence.
However, the inclusion of insertions changed the relative
positions of each nucleotide within the annotated hGR se-
quence, so a nucleotide position identifier (UhGR #) col-
umn was added to the visualization sheet. Each variant ID
in the database was then associated with a UhGR # that dy-
namically updated whenever more information was added
to the hGR sequence. This allows users to easily track the
visual changes in the database as more data is accumulated.
The Universal hGR database will be made available to
the public and maintained/curated in our laboratory.
Although the Universal hGR will ultimately expand to
be more than a data management system, many guide-
lines for LSDBs will be followed [36, 37]. Data will be
available to download from a university-hosted website
(http://somapp.ucdmc.ucdavis.edu/shriners/uhgr) after
users provide basic user information and consent to
relevant disclosures, such as indicating that the data is
not for diagnostic or commercial purposes. By
self-hosting the database, we can ensure its long-term
continuance, security, and maintenance on a secure, uni-
versity server. The database will be regularly backed up
to a secondary source to prevent any potential, unfore-
seeable loss of data. To promote usage, the database will
be submitted to LSDB lists, such as https://grenada.-
lumc.nl/LSDB_list/lsdbs/NR3C1. The database will re-
lease updated versions to incorporate new findings from
our lab, public databases and publications, and user sub-
mitted data. Data from external sources will not be sub-
jected to internal quality control procedures; however,
their source information will be provided. The majority
of outside variants in the Universal hGR were collected
from dbSNP and dbVar and were therefore subjected to
NCBI’s own quality control [38, 39].
Fig. 5 Insertions and deletions in hGR. Additions and deletions are indicated with vertical lines in the hGR sequence. Deletions are shown in red
with the nucleotide or number of nucleotides removed, and additions are shown in black with nucleotide or number of nucleotides added.
Domains are represented with shading. a Additions and deletions found during our laboratory’s screening of hGR (above). b Additions and
deletions cataloged from the publication and database survey
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Fig. 6 Universal hGR database (screenshots). The different sections comprising the UhGR are shown: list of Source Data; annotated Databases of
the insertions, deletions, and SNPs with the unique identifiers corresponding to the clones (CloneID), variants (Variant ID), and dynamically
changing hGR location (UhGR #); and the hGR sequence amended with the new variants (Sequence)
Leventhal et al. BMC Genetics           (2019) 20:16 Page 9 of 15
Discussion
We are far from understanding hGR regulation and the
newly identified variants indicate that the process may
be more complex than previously thought. To date, there
are over 2000 SNPs, 40 insertions, 139 deletions, and 26 al-
ternative splice variants identified from our screenings and
survey of databases and publications. In various combina-
tions, these can form numerous unique hGR isoforms that
may be potentially expressed. Although many reported mu-
tations are only linked to subclinical or no manifestations,
there are some studies showing deletions [40, 41] and SNPs
[42–46] that have been shown to disrupt patient homeosta-
sis; this justifies the need for further investigation into our
newly identified isoforms. The expression of one or more
of the countless combinations of these variants may explain
the highly inconsistent individual responses to stress.
Functional analysis data for several new variants suggests
that an individual’s unique hGR profile affects responsive-
ness to stress and glucocorticoid treatment. An isoform
containing one SNP, A829G (NM_000176.2:c.829A >G,
p.Lys277Glu), has been shown to result in an in vitro trans-
activation potential that varied depending on the type and
dosage of glucocorticoid treatment [47]. Similarly, isoforms
with either the T1463C SNP (NM_000176.2:c.1463 T >C,
p.Leu488Pro) or the A2297G SNP (NM_000176.2:c.229
7A >G, p.Asn766Ser) were found to have low baseline ac-
tivity but a hyperactive response, relative to hGRα, when
treated with glucocorticoids. Interestingly, while the
T1463C isoform was hyperactive when treated with hydro-
cortisone, methylprednisolone, and dexamethasone, the
A2297G isoform showed an augmented response to hydro-
cortisone treatment only [48]. Although some hGR variants
alone are insufficient to elicit a response to glucocorticoids,
their presence in combination with other variations can
confer a synergistic effect, as demonstrated by the afore-
mentioned A2297G SNP which was originally found in
conjunction with A214G (NM_000176.2:c.214A >G, p.Asn
72Asp) and T962C (NM_000176.2:c.962 T >C, p.Val321
Ala). Single SNP constructs containing either the A214G or
the T962C SNPs had little to no baseline activity compared
to hGRα; however, when combined with the hyperactive
A2297G SNP, the multi-variant isoform had greater activity
than any of the single SNP constructs [49]. Although func-
tional characterization is still needed for many more variant
isoforms, these initial findings illustrate how these isoforms
can alter responsiveness to glucocorticoids in a type-, dose-,
and variant combination-dependent manner.
In addition to examining the responsiveness of these
new hGR isoforms, the mechanisms of their activity
merits further study to understand their impact on differ-
ential patient response. The simplest explanation may be
that the hGR variants have modified DNA or ligand bind-
ing properties [50–53]. The variants could also indirectly
affect the function of other transcription factors such as
NF-κB and AP-1. The structural changes in the isoforms
could also significantly alter receptor degradation,
post-translational modification, chaperone binding, or
dimerization properties. Another possibility is that the
variant receptors utilize an unknown non-canonical acti-
vation pathway. Future large studies in mice, which have
been shown to also express both GRα and GRβ isoforms
[54, 55], may be employed to confirm isoform activity and
to shed light on their mechanisms. This will allow us to
understand how to influence the expression of these
variants in patients and thereby directly impact their per-
sonalized treatment regimens.
The vast diversity and multiple functions of the gene is
only becoming more apparent as developing technologies
and alternative approaches to studying hGR have allowed
for more sensitive analysis. Many previous studies have
been limited by their focus on cell lines, rather than
samples directly from volunteers or patients [56–58].
Additionally, other studies often focus on specific portions
of the gene using techniques such as PCR or sequencing,
which rely on primers designed to match target sequences
and therefore may not detect alternate variants. Many
studies also only look at select, previously reported vari-
ants [59, 60], or at ones expressed in subjects that present
with medical conditions, such as generalized glucocortic-
oid resistance [61, 62]. By utilizing exon-to-exon screening
as well as employing primary cells from human subjects,
we were able to detect a significantly greater number of
hGR isoform variations in both healthy (volunteers and
Leukopaks) and stressed (burn and asthma patients)
populations.
Although the frequency of specific variants was not eval-
uated, a survey of the database reaffirmed the prevalence of
several commonly reported variants, such as the N363S
SNP (rs56149945), but more importantly it highlights new
areas that may be significant in the stress response system.
One novel SNP, A1476C (NM_000176.2:c.1476A >C), was
frequently found in multiple volunteer samples. The
A1476C SNP causes an amino acid change of lysine to as-
paragine at position 492 [NM_000176.2:p.(Lys492Asn)] in
the hinge region. As expected, the two largest domains, the
transactivation domain and LBD, have the most variants;
however, the hinge region was revealed to have a similar
number of deletions despite being significantly smaller. This
could indicate that the hinge region, which has been less
studied but thought to play a role in protein conformation,
may be worth further investigation [63]. Additionally, the
abundance of new exons discovered demonstrates that the
NR3C1 gene is more complex than the current conven-
tional structure. Similar to hGRβ, the hGR-H variant (with
retained intron H) has been detected in all volunteer and
patient samples with varying levels of expression [35]. Fur-
ther research into these areas may help elucidate the role of
hGR in individual stress response variations.
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As we expand our variant database, it is essential to
maintain a dynamic annotation system for the hGR data
in order to efficiently analyze the pattern of isoform ex-
pression. Due to the large number of variants cataloged,
these expression patterns may not be readily apparent.
In 2003, when researchers reported on hGR variants ag-
gregated from different sources, the need for a LSDB for
the hGR gene, NR3C1, was acknowledged [64]. Al-
though there are a few open source variation databases
reported for hGR (https://grenada.lumc.nl/LSDB_list/
lsdbs/NR3C1), many of them are defunct. The remaining
LSDBs contain data for only a small number of variants,
and many have not been kept up-to-date. This leaves
only the genome-wide NCBI databases, the SNP data-
base (dbSNP) and the non-SNP variation database
(dbVar), which allow for user submission of variants and
incorporates data sets from large studies (such as the
1000 Genomes project), as well as the Database of Gen-
omic Variants archive (DGVa) from the European Bio-
informatics Institute. The GWAS Central (formerly
HGVbase, https://www.gwascentral.org) is also available,
but only reports an incomplete list of dbSNP data.
Although NCBI’s databases have a sizeable number of
variants cataloged, they have several limitations, such as
not being intuitive to navigate, accepting non-validated
data, and not allowing for demographic information to
be submitted to dbSNP or dbVar.
Our UhGR provides a centralized and customized
database to store hGR data that will allow for better
visualization and analysis of data. Ultimately, the UhGR
will become the basis for a formal software suite which
will be publically accessible and adaptable for other
genes. By supplementing each variant with easy to navi-
gate and sortable information, such as the sample source
(e.g. deidentified/anonymized human subject data) and
linked changes, trends will be easier to detect. Although
the database will not be for diagnostic use, we expect
that correlations between variants and clinical data will
ultimately reveal patterns which may serve as markers
for sepsis and other physiological stresses, as well as help
predict individual response to stress and steroid treat-
ment that may prove an important step in personalizing
patient therapy regimens.
Conclusion
Our study indicates that the hGR has more variants at
the RNA and DNA levels than previously believed. This
information is aggregated in our database, which in-
cludes our 21 new splice variants and over 1300 SNPs
from primary cells of human subjects. Although more
research needs to be done to investigate the mechanisms
of how all these hGR variants play a role in divergent
responses to a range of stressors, these findings have
wide-scale implications in explaining the dynamic and
individual-specific variability in responsiveness to gluco-
corticoid treatment and eventually personalizing patient
treatment regimens.
Methods
Study populations
All protocols involving the collection, processing, and ana-
lysis of human blood samples in this study were approved
by the Institutional Review Board of the University of
California, Davis. Written informed consent was obtained
from participants in this study.
To examine the baseline hGR profiles of healthy volunteer
subjects, individuals with a history of major illness (diabetes
mellitus, hypertension, chronic obstructive pulmonary dis-
ease, inflammatory bowel disease, autoimmune disease, and
cancer), pregnant women, and individuals taking exogenous
steroids were excluded. The final volunteer population was
a mixed cohort of 97 people (70 female and 27 male; ages
20–67) made up of approximately one-half Caucasians, one
quarter Asians, with the remaining one quarter being
African Americans, Hispanics, or other [49].
To screen for stress-induced hGR variations expressed
through a patients’ clinical course, blood was collected
from 110 patients with ≥20% total body surface area
burns after admission to the UC Davis Medical Center
and Shriners Hospitals for Children Burn Units. Samples
were collected at regular 2-week intervals as well as ad-
ditional draws during septic episodes. The 110 patients
(82 men and 28 women) were composed of approxi-
mately half adults (18 years of age or older). Of the 110
enrolled patients, 18 were selected for further analysis.
This group consisted of 13 men and 5 women; and 39%
adults and 61% minors. The first eight patients were se-
lected due to their early enrollment in the study, while
the remaining patients were selected for having samples
with the greatest number of time points.
Additionally, 35 patients with differential responses to
steroid treatment were enrolled in an asthma study at
the University of California Asthma Network Clinic. As
an adjunct study, their genomic DNA was examined for
hGR profiles.
Finally, as an in vitro study of stress response, peri-
pheral blood leukocytes were isolated from blood donors
using “Leukopaks” purchased from BloodSource
(Mather, CA), a local blood bank. Leukopak “1” came
from a 50-year-old female, while Leukopaks “2” and “3”
were from adult males, ages 53 and 64 respectively. No
additional demographic information was provided.
Identification of hGR isoforms
Human subjects (our laboratory)
For the 97 volunteers, the enriched buffy coat samples
were erythrocyte-lysed using Buffer EL (Qiagen, Valencia,
CA). For the 18 select burn patients, the enriched buffy
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coat samples were lysed using TRIzol reagent (Thermo-
Fisher, Waltham, MA). Samples from both populations
then had RNA extracted using the RNeasy Mini Kit
(Qiagen). Reverse transcriptase-polymerase chain reaction
(RT-PCR) using the Sensiscript RT Kit (Qiagen) was
performed to amplify the hGR coding sequence in two
sections (exons 2–3 and exons 3–9) for the volunteers
(Additional file 1: Table S1). Using the genomic DNA
from asthma patients, each exon was PCR amplified indi-
vidually. In burn patient samples, RT-PCR was performed
using a QuantiTect RT Kit (Qiagen) to amplify full length
hGR or sequential hGR exon-to-exon combinations for a
more sensitive analysis. RT-PCR was also done using
cDNA from tsA201 cells (a transformed HEK293 cell line
authenticated by ATCC- via STR profiling,) as a positive
protocol control while screening for the cDNA ends.
tsA201 cells were a gift from Dr. Daniel Feldman at
Shriners Hospitals for Children Northern California. All
fragments were cloned into a pGEM-T Easy vector
(Promega, Madison, WI) or a pCR-BluntII-TOPO vector
(ThermoFisher) then sent for Sanger sequencing at
MCLAB (South San Francisco, CA) or GeneWIZ (South
Plainfield, NJ). Since Sanger sequencing has distinct ad-
vantages relative to alternative methods, such as high ac-
curacy and longer reads, it was determined to be the
optimal method to screen a single gene for potentially
large variants (e.g., splicing events) in a transcript. Variants
were identified by comparison to the National Center for
Biotechnology Informatics (NCBI) hGRα reference se-
quence (NM_000176.2 or NG_009062.1).
Leukopaks (our laboratory)
Leukopaks, a white blood cell concentrate prepared from
leukoreduced whole blood, were purchased from Blood-
Source (Sacramento, CA). Peripheral blood mononuclear
cells (PBMCs) were separated using a Histopaque-1077
gradient (Sigma, St. Louis MO) and treated with
Ammonium-Chloride-Potassium (ACK) buffer to lyse
any remaining red blood cells. Cells were resuspended in
RPMI-1640 media (ThermoFisher) supplemented with
10% fetal bovine serum (Atlanta Biologicals, Lawrence-
ville, GA) and seeded in 6-well plates at 9.7 × 106–10.0 ×
106 cells per well, then incubated at 37 °C in a 5% CO2
atmosphere for 1 h before treatment. Each treatment
condition was done in triplicate. To investigate the effect
of stress (e.g., exposure to bacterial products as a conse-
quence of burn injury) on hGR isoform expression, cells
were exposed to lipopolysaccharide (LPS) from E. coli
serotype 026:B6 (Sigma). For Leukopak 1, cells were
treated with LPS at 5 μg/mL or 10 μg/mL, or with
diluent only (i.e. sterile water) as a baseline. For Leuko-
paks 2 and 3, cells were treated with 5 μg/mL LPS, 1 μM
pharmaceutical-grade hydrocortisone sodium succinate
(Pfizer, New York, NY), 5 μg/mL LPS with 1 μM
hydrocortisone, 10 μg/mL LPS with 1 μM hydrocorti-
sone, or saline diluted with water to match the 5 μg/mL
LPS with hydrocortisone condition. Cells were collected
after 1, 3, and 13 h. RNA was isolated using the RNeasy
Mini Kit (Qiagen), cDNA prepared using the QuantiTect
RT Kit (Qiagen), and PCR was performed to amplify
both full length hGR and different hGR exon-to-exon
combinations (Additional file 1: Table S1). DNA was
cloned into a pGEM-T Easy vector (Promega) then se-
quenced (MCLAB). All variants, relative to the hGRα
reference sequence, were documented.
Database and publication survey
Several databases were screened for published variants.
Using the NCBI Variation Viewer (http://www.ncbi.nlm.-
nih.gov/variation/), the database of Short Genetic Varia-
tions (dbSNP) [13] and the database of Genomic
Structural Variation (dbVar) [65] were examined for
exons two through nine of the NR3C1 (hGR) gene
(NM_000176.2), the intronic sections corresponding to
the new cryptic exons, and all of intron H. All reported
SNPs, insertions, and deletions in those regions were re-
corded, along with their corresponding accession num-
bers (rs#). At this time, duplication events (e.g., copy
number variation and short tandem repeat variation)
Fig. 7 Schema of the Universal hGR database. Data from various
sources are collected and curated to identify hGR variants. The
analyzed information is assigned unique data tracking identifiers.
The changes are appended to the reference hGR sequence, which
may result in a revised nucleotide sequence. These changes are
annotated with dynamically-adjusting UhGR location identifiers that
allow the user to locate specific variants. The adjusted sequence is
displayed on an Excel worksheet, along with the lists of variants
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and non-deletion genetic rearrangements (e.g., transloca-
tion and inversion) were not included. Other databases
screened for those regions were the Global Variome shared
LOVD (https://databases.lovd.nl/shared/genes/NR3C1), Lei-
den Open Variation Database (http://proteomics.bio21.uni-
melb.edu.au/lovd/genes/NR3C1), and BIPMed SNP Array
(http://bipmed.iqm.unicamp.br/snparray/genes/NR3C1).
In addition to databases, a detailed search of PubMed
(http://www.ncbi.nlm.nih.gov/pubmed/) was performed
for papers published in the past 10 years using the fol-
lowing terms: “human glucocorticoid receptor” AND
“polymorphism”, “human glucocorticoid receptor” AND
“variant”, “human glucocorticoid receptor” AND “spli-
cing”, “human glucocorticoid receptor” AND “addition”,
“human glucocorticoid receptor” AND “deletion”, and
“human glucocorticoid receptor” AND “mutation.” Any
published variants not in databases were documented.
hGR database (Universal hGR) construction
For the creation of an hGR-specific database, three data
types were used as sources of information for variants:
data from published reports, data from available data-
bases, and from our laboratory. This data was organized
by initially assigning each data source or clone a unique
identifier. Data from each source was mined to identify
background information and variants. Each unique
change (SNP, insertion, or deletion) was assigned an-
other unique identifier and this information was also
added to the database (Fig. 7).
The collected data was used to construct the UhGR
framework. Using the NCBI hGR reference sequence
(NM_000176.2) as the backbone, basic information such
as coding protein and chromosome locations were
noted. Variant data (SNP, insertion, and deletion) was
annotated onto the sequence. Since the size of the se-
quence changes after each insertion data is added, a
UhGR nucleotide location number was created, which
references the current location of the variant. The up-
dated hGR sequence with the annotated variants can
then be viewed by the user.
Additional file
Additional file 1: Table S1. PCR primer sequences for hGR screening.
(XLSX 13 kb)
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